INOVIO AS
INOVIO AS
Social Links:
Industry:
Biotechnology Genetics
Address:
Oslo, Oslo, Norway
Country:
Norway
Total Employee:
1+
Status:
Active
Similar Organizations
Love At First Swab
Love At First Swab is a biotechnology company.
More informations about "Inovio AS"
Leadership | INOVIO Pharmaceuticals
She led INOVIO’s manufacturing, commercial, business development, project and alliance management operations. Dr. Shea has more than 25 years of …See details»
INOVIO Pharmaceuticals
INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. We use proprietary technology to …See details»
Inovio AS - Crunchbase Company Profile & Funding
Inovio AS is an Oslo, Norway-based gene delivery technology company. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. ... 308 Number of …See details»
Inovio Pharmaceuticals, Inc. - INOVIO Highlights Anticipated 2025 ...
Jan 9, 2025 INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, …See details»
Inovio Pharmaceuticals, Inc. - INVESTORS & MEDIA
INOVIO's Board of Directors has five standing committees. Each committee member meets the independence requirements of the NASDAQ, the definition of a "non-employee director" under …See details»
Inovio Pharmaceuticals, Inc. - INOVIO Announces Corporate ...
Jul 19, 2022 "By driving operational efficiencies throughout our organization, we are focused on advancing our lead pipeline candidates toward commercialization and optimizing our chances …See details»
Purpose, Mission and Values | INOVIO Pharmaceuticals
INOVIO is a clinical-stage biotechnology company committed to advancing DNA medicines to help save and protect lives worldwide. We are trailblazers in the DNA medicine field, working …See details»
Inovio Pharmaceuticals - Funding, Financials, Valuation & Investors
Inovio Pharmaceuticals has acquired 2 organizations. Their most recent acquisition was Bioject Medical Technologies on May 2, 2016 . They acquired Bioject Medical Technologies for $4.3M .See details»
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key …
Jan 9, 2025 INO-3107 . Anticipated Milestones for 2025. Submit BLA to the U.S. Food and Drug Administration (FDA) by mid-2025 and request priority review. INO-3107 could be the …See details»
Mission Statement, Vision, & Core Values (2025) of Inovio ...
[relinking] Home Overview Mission Vision Values An Overview of Inovio Pharmaceuticals, Inc. (INO) General Summary of Inovio Pharmaceuticals, Inc. (INO) Inovio Pharmaceuticals, Inc. is …See details»
INOVIO Announces Corporate Reorganization to Reduce …
Jul 19, 2022 INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to potentially treat and protect people from infectious diseases, cancer, and …See details»
Inovio Pharmaceuticals, Inc. - INOVIO Reports Fourth Quarter and …
Mar 18, 2025 PLYMOUTH MEETING, Pa., March 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines …See details»
INOVIO Announces Strategic Reorganization, Continues Efforts to …
Jan 31, 2023 Data readouts for INOVIO's Phase 3 REVEAL2 trial for VGX-3100 and the second cohort from the Phase 1/2 trial for INO-3107 are expected to be announced in the first quarter …See details»
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key …
Jan 9, 2025 INOVIO's partner, ApolloBio, continues recruitment into its Phase 3 trial evaluating INO-3100 as a potential treatment for HPV 16/18 positive cervical dysplasia in China. General …See details»
Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights ...
6 days ago Inovio Pharmaceuticals Inc (NASDAQ:INO) has resolved the manufacturing issue with the single-use array component of the Selectra device, which is crucial for their BLA …See details»
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key ...
Jan 9, 2025 INOVIO's partner, ApolloBio, continues recruitment into its Phase 3 trial evaluating INO-3100 as a potential treatment for HPV 16/18 positive cervical dysplasia in China. General …See details»
Inovio CEO sees 2025 to be ‘transformational year’
Jan 9, 2025 Inovio highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings, with President and Chief Executive Officer …See details»
INOVIO Reports Fourth Quarter and Full Year 2024 Financial
6 days ago PLYMOUTH MEETING, Pa., March 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines …See details»
Inovio Pharmaceuticals, Inc. - INOVIO Announces Strategic ...
Jan 31, 2023 Data readouts for INOVIO's Phase 3 REVEAL2 trial for VGX-3100 and the second cohort from the Phase 1/2 trial for INO-3107 are expected to be announced in the first quarter …See details»
The best companies are the ones reinventing how they manage
Mar 14, 2025 Successful organizations create clear pathways for new management practices to emerge and evolve. Kyocera's amoeba management system provides a structured approach …See details»